3rd Pre- Connect Congress 2017

Women in Pharma Speakers

Marina Wyatt

Chief Financial Officer and Executive Director

UBM

Camilla Harder Hartvig

President

Europe and Emerging Markets

member of the Executive Leadership Team and Head of Region Europe & Emerging Markets

Glenmark Pharmaceuticals

Ms. Camilla Hartvig joined earlier this year as President, Europe and Emerging Markets, Member of the Executive Leadership Team and Head of Region Europe & Emerging Markets, Glenmark Pharmaceuticals. She is a member of the executive team and head of the region serving Europe, Latin America, Russia/CIS and South East Asia.

Before joining Glenmark Pharmaceuticals, Ms. Hartvig worked for Allergan Inc. as Regional President and for AstraZeneca where she amongst other roles was Country President of AZ Spain and Head of Global Marketing. Ms. Hartvig has also spent several years with Novartis leading BUs and sales teams in both Denmark and the U.K. She started her career as a medical representative.

Ms. Hartvig previously served as VP on the Pharma industry board in Spain and is now a board member of C-worldwide, a Danish investment fund.

She holds master degrees from Copenhagen Business School (CBS) in Denmark and Ecole des Hautes Etude Commerciale (HEC), París, France. To further educate herself Ms. Hartvig has also taken an advertisement agency education by IAA, an executive board education at INSEAD and latest she is a graduate of GiANT Worldwide's Xcore leadership thinking (Liberating Leadership).

Ms. Hartvig is married to Thomas and together they have 4 kids between the age of 10-17. The family has in connection with Ms. Hartvig’s progressing career lived together in Copenhagen, London, Brussels, Madrid and Stockholm, while she has also lived 3 years in Paris. Her husband supports her fully in her career and is therefore the one at home and in charge of the family.

Namita Thapar

CFO & Executive Board Member

Emcure Pharmaceuticals

Mrs. Namita Thapar is a Chartered Accountant from ICAI and MBA from the Fuqua School of Business. She is currently the Chief Financial Officer and Executive Board Member at Emcure Pharmaceuticals-a global pharmaceutical company headquartered in Pune with a turnover of over 4000 crores. It has presence in over 60 countries and an employee strength of over 10,000.

Prior to joining Emcure, Mrs. Thapar has worked overseas for 6 years in various roles including finance and marketing at Guidant Corporation (now Abbott - Stent business). Since joining Emcure in 2007, she manages multifunctional portfolios like Finance, Domestic Marketing and HR. She manages the pan India operations of over 3000 medical representatives contributing to over 1000 crores in sales.

In addition, Mrs. Thapar is on the board of Finolex Cables as well as on the board of the Fuqua School of Business (Duke University). She is also the founder and CEO of Incredible Ventures Ltd, an education company that teaches entrepreneurship to 11 -18 year olds in Mumbai, Delhi, Bangalore and Hyderabad.

Mrs. Thapar is also a member of the Young Presidents Organization, Pune. and a recipient of the prestigious Economic Times ‘40 under Forty’ award. She is a part of the ‘Champions of Change’ program initiated by PM Narendra Modi for G2B partnership in policymaking. Mrs. Namita Thapar is married to Vik Thapar and they have two beautiful children.

Ekta Batra

Sr. Research Analyst & Anchor

CNBC TV18

Ms. Ekta Batra has been with CNBC-TV18 since October 2008. She is a Senior Research Analyst, Anchor and a part of the editorial team of the channel. Ms. Batra anchors and produces shows such as ’Power Breakfast’ and ‘Markets & Macros’. She also handles fundamental research on macroeconomics, banks, NBFCs, pharmaceuticals and healthcare sectors. Ms. Batra holds a Masters Degree in Business Management from University of Warwick, England and a Bachelors Degree (with Honors) in Business and Communication from Ithaca College, New York. Prior to working with CNBC-TV18, Ms. Ekta Batra has worked on projects with McKinsey & Company and Bank of America Merrill Lynch as an Investment Associate.